06:58 AM EDT, 09/03/2025 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said Wednesday that it has submitted an investigational new drug application to the US Food and Drug Administration for IDE892, a new drug designed for patients with MTAP-deleted solid tumors in lung cancers.

The company said it plans to begin an early-stage dose escalation trial of IDE892 in MTAP-deleted lung cancer in Q4, with the goal of advancing into combination studies with its other drug, IDE397, in H1 of next year.

About 15% to 20% of non-small cell lung cancers have MTAP deletions, the company said.

Ideaya said that in addition to MTAP-deleted lung cancer, it plans to clinically evaluate other MTAP solid tumor indications as both IDE892 monotherapy and in combination with IDE397.